Lv1
75 积分 2020-08-03 加入
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC
23小时前
求助中
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
1天前
已完结
EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-mutant NSCLC with high PD-L1 expression: a real-world retrospective study
29天前
已完结
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
1个月前
已完结
Pemetrexed-Based Chemotherapy in Advanced Lung Adenocarcinoma Patients With Different EGFR Genotypes.Jiang X, Yang B, Lu J, et al.Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine
1个月前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
1个月前
已完结
Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes
1个月前
已完结
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
1个月前
已完结
Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer,
1个月前
已完结
Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline
1个月前
已完结
皖公网安备34019202002308
